Ved Bhushan Arya1, Qadeer Aziz2, Azizun Nessa3, Andrew Tinker2, Khalid Hussain1,4. 1. London centre for Paediatric Endocrinology, Great Ormond Street Hospital for Children NHS Foundation Trust, London WC1N 3JH and The Institute of Child Health, University College London, London, WC1N 1EH UK. 2. The Heart Centre, William Harvey Research Institute, Barts and the London School of Medicine and Dentistry, Charterhouse Square, London, UK. 3. The Institute of Child Health, University College London, London, WC1N 1EH UK. 4. Developmental Endocrinology Research Group, Molecular Genetics Unit, Institute of Child Health, University College London, 30 Guilford Street, London, WC1N 1EH UK.
Abstract
BACKGROUND: Mutations in ABCC8 and KCNJ11 are the most common cause of congenital hyperinsulinism (CHI). Recessive as well as dominant acting ABCC8/KCNJ11 mutations have been described. Diazoxide, which is the first line medication for CHI, is usually ineffective in recessive ABCC8 mutations. We describe the clinical and molecular characterisation of a recessive ABCC8 mutation in a CHI patient that is diazoxide response. CLINICAL CASE: A term macrosomic female infant presented with symptomatic persistent hypoglycaemia confirmed to be secondary to CHI. She exhibited an excellent response to moderate doses of diazoxide (10 mg/kg/day). Molecular genetic analysis of the proband confirmed a biallelic ABCC8 mutation - missense R526C inherited from an unaffected mother and a frameshift c.1879delC mutation (H627Mfs*20) inherited from an unaffected father. Follow-up highlighted persistent requirement for diazoxide to control CHI. Functional analysis of mutants confirmed them to result in diazoxide-responsive CHI, consistent with the clinical phenotype. CONCLUSION: Biallelic ABCC8 mutations may result in diazoxide-responsive CHI. Irrespective of the molecular genetic analysis results, accurate assessment of the response to diazoxide should be undertaken before classifying a patient as diazoxide-responsive or unresponsive CHI.
BACKGROUND: Mutations in ABCC8 and KCNJ11 are the most common cause of congenital hyperinsulinism (CHI). Recessive as well as dominant acting ABCC8/KCNJ11 mutations have been described. Diazoxide, which is the first line medication for CHI, is usually ineffective in recessive ABCC8 mutations. We describe the clinical and molecular characterisation of a recessive ABCC8 mutation in a CHI patient that is diazoxide response. CLINICAL CASE: A term macrosomic female infant presented with symptomatic persistent hypoglycaemia confirmed to be secondary to CHI. She exhibited an excellent response to moderate doses of diazoxide (10 mg/kg/day). Molecular genetic analysis of the proband confirmed a biallelic ABCC8 mutation - missense R526C inherited from an unaffected mother and a frameshift c.1879delC mutation (H627Mfs*20) inherited from an unaffected father. Follow-up highlighted persistent requirement for diazoxide to control CHI. Functional analysis of mutants confirmed them to result in diazoxide-responsive CHI, consistent with the clinical phenotype. CONCLUSION: Biallelic ABCC8 mutations may result in diazoxide-responsive CHI. Irrespective of the molecular genetic analysis results, accurate assessment of the response to diazoxide should be undertaken before classifying a patient as diazoxide-responsive or unresponsive CHI.
Authors: H Huopio; F Reimann; R Ashfield; J Komulainen; H L Lenko; J Rahier; I Vauhkonen; J Kere; M Laakso; F Ashcroft; T Otonkoski Journal: J Clin Invest Date: 2000-10 Impact factor: 14.808
Authors: K E Snider; S Becker; L Boyajian; S-L Shyng; C MacMullen; N Hughes; K Ganapathy; T Bhatti; C A Stanley; A Ganguly Journal: J Clin Endocrinol Metab Date: 2012-12-28 Impact factor: 5.958
Authors: Benjamin Dekel; Daniel Lubin; Dalit Modan-Moses; Jacob Quint; Benjamin Glaser; Joseph Meyerovitch Journal: Clin Pediatr (Phila) Date: 2002-04 Impact factor: 1.168
Authors: Courtney M Macmullen; Qing Zhou; Kara E Snider; Paul H Tewson; Susan A Becker; Ali Rahim Aziz; Arupa Ganguly; Show-Ling Shyng; Charles A Stanley Journal: Diabetes Date: 2011-05-02 Impact factor: 9.461
Authors: R R Kapoor; S E Flanagan; C T James; J McKiernan; A M Thomas; S C Harmer; J P Shield; A Tinker; S Ellard; K Hussain Journal: Diabetologia Date: 2011-06-15 Impact factor: 10.122
Authors: Ritika R Kapoor; Sarah E Flanagan; Ved Bhushan Arya; Julian P Shield; Sian Ellard; Khalid Hussain Journal: Eur J Endocrinol Date: 2013-03-15 Impact factor: 6.664
Authors: Maria Salomon-Estebanez; Sarah E Flanagan; Sian Ellard; Lindsey Rigby; Louise Bowden; Zainab Mohamed; Jacqueline Nicholson; Mars Skae; Caroline Hall; Ross Craigie; Raja Padidela; Nuala Murphy; Tabitha Randell; Karen E Cosgrove; Mark J Dunne; Indraneel Banerjee Journal: Orphanet J Rare Dis Date: 2016-12-01 Impact factor: 4.123